Although the prevalence of distal sensory peripheral neuropathy has decreased in resource-limiting settings following initiation of combination antiretroviral therapy (CART) in people living with HIV (PLWHIV), better strategies are required, according to research, to prevent or enhance residual distal sensory peripheral neuropathy after initiation of CART. A complication of the human immunodeficiency virus is distal sensory peripheral neuropathy (DSPN) (HIV). Compared to match participants not living with HIV and virally suppressed in PLWH on 1 of 3 cART regimens, we estimate DSPN prevalence in 7 resource-limited settings (RLSs) for combination antiretroviral therapy (cART)-naive persons living with HIV (PLWH). The distinction between HIV-associated DSPN and antiretroviral toxic neuropathy caused by reverse transcriptase inhibitors of dideoxynucleoside ('d-drugs') can be difficult. In the past, d-drugs were widely used in resource-limited settings (RLSs) as an effective and inexpensive ART. There is also a greater availability of less neurotoxic cART regimens. However, among cART-experienced PLWH who were never exposed to d-drugs, a study in Kenya showed a continued burden of DSPN (33.8 percent). It is currently unclear whether the path of HIV-associated DSPN may be avoided or altered by early initiation of cART. Before cART initiation, DSPN was observed in acute and primary HIV infection. In primary HIV infection, symptomatic DSPN was associated with elevated inflammatory markers as opposed to asymptomatic DSPN. Thus, it could be argued that while DSPN in acute HIV infection would be difficult to avoid, early initiation of cART could minimize its severity by decreasing systemic inflammation. The main aim of our journal (Journal of HIV and AIDS Research) is to draws readers' attention to the latest advances in HIV research in the fields of prevention, care and cure. The peoples who are interested to publish their article they can submit their manuscripts in our journal through given link: https://www.scholarscentral.org/submissions/hiv-aids-research.html

Ella Addison

Managing Editor

Journal of HIV and AIDS Research

Mail ID: aids@emedicaljournals.org

WhatsApp no: + 1-504-608-2390